Ivermectin (IVM) could cause potential neurotoxicity; however, the precise molecular mechanisms remain unclear. This study explores the cytotoxicity of IVM in human neuroblastoma (SH-SY5Y) cells and the underlying molecular mechanisms. The results show that IVM treatment (2.5-15 μM) for 24 h could induce dose-dependent cell death in SH-SY5Y cells. Compared to the control, IVM treatment significantly promoted the production of ROS, mitochondrial dysfunction, and cell apoptosis. IVM treatment also promoted mitophagy and autophagy, which were charactered by the decreased expression of phosphorylation (p)-Akt and p-mTOR proteins, increased expression of LC3II, Beclin1, ATG5, PINK, and Pakin1 proteins and autophagosome formation. N-acetylcysteine treatment significantly inhibited the IVM-induced production of ROS and cell death in SH-SY5Y cells. Autophagy inhibitor (e.g., 3-methyladenine) treatment significantly inhibited IVM-induced autophagy, oxidative stress, and cell apoptosis. Taken together, our results reveal that IVM could induce autophagy and apoptotic cell death in SH-SY5Y cells, which involved the production of ROS, activation of mitochondrial pathway, and inhibition of Akt/mTOR pathway. Autophagy inhibition improved IVM-induced oxidative stress and apoptotic cell death in SH-SY5Y cells. This current study provides new insights into understanding the molecular mechanism of IVM-induced neurotoxicity and facilitates the discovery of potential neuroprotective agents.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137967PMC
http://dx.doi.org/10.3390/antiox11050908DOI Listing

Publication Analysis

Top Keywords

sh-sy5y cells
24
cell death
20
death sh-sy5y
16
apoptotic cell
12
oxidative stress
12
ivm treatment
12
production ros
12
mitochondrial pathway
8
molecular mechanisms
8
treatment promoted
8

Similar Publications

Background: The nuclear clearance and cytoplasmic aggregation of splicing repressor TAR DNA/RNA-binding protein-43 (TDP-43) occur in approximately 50% of Alzheimer's disease (AD) cases and about 45% of frontotemporal dementia (FTD). However, it is not clear how early such mechanism occurs in AD and FTD as there is no method of detecting TDP-43 dysregulation in living individuals. Since the loss of nuclear TDP-43 leads to cryptic exon inclusion, we propose that cryptic exon-encoded peptides may be detected in patient biofluids as biomarkers of TDP-43 loss of function.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

All India Institute of Medical Sciences, New Delhi, India.

Background: Recent research on Alzheimer's disease (AD) has highlighted that the oxidative damage is the earliest event of disease. These oxidative modifications are closely associated with inflammatory molecules. It is necessary to explore these two pathways with AD pathophysiology and targeted for therapeutic intervention.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

All India Institute of Medical Sciences, AIIMS, New Delhi, Delhi, India.

Background: Alzheimer's disease (AD) is a progressive brain disorder which leads to gradual decline in memory, thinking, behaviour and social skills. The current scenario for drug development is based on neuro-inflammation and oxidative stress. Amyloid-β (Aβ) deposition, a major hallmark of the disease activates microglia leading to neuro-inflammation and neuro-degeneration induced by activation of COX-2 via NFkB p50 in glioblastoma cells.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

IMDEA Nanociencia, Madrid, Spain.

Background: About half of the patients suffering from Alzheimer's disease (AD) display sleeping disorders. Disruptions in the central circadian clock (CC), located in the brain, accelerate AD pathogenesis, making the CC a promising target. In preclinical trials, this strategy have shown efficacy but clinical results are inconsistent.

View Article and Find Full Text PDF

Background: Recent work suggests that amyloid precursor protein (APP) may be involved in regulating mitochondrial quality control mechanisms. Impaired mitophagy, leading to the accumulation of damaged mitochondria are features of Alzheimer's disease (AD). Conversely, enhancing mitophagy may reduce AD neuropathological change and improve cognitive function.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!